Aura Biosciences, Inc. (NASDAQ:AURA – Get Rating) major shareholder Matrix Capital Management Comp purchased 1,250,000 shares of Aura Biosciences stock in a transaction on Monday, December 5th. The stock was acquired at an average cost of $12.00 per share, for a total transaction of $15,000,000.00. Following the acquisition, the insider now directly owns 5,362,870 shares of the company's stock, valued at $64,354,440. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Aura Biosciences Stock Up 2.8 %
Shares of NASDAQ AURA opened at $12.78 on Friday. Aura Biosciences, Inc. has a 12-month low of $11.29 and a 12-month high of $24.83. The firm's 50-day moving average is $13.28 and its two-hundred day moving average is $14.42.
Get Aura Biosciences alerts:Aura Biosciences (NASDAQ:AURA – Get Rating) last announced its quarterly earnings data on Thursday, November 10th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.01). As a group, equities analysts predict that Aura Biosciences, Inc. will post -2.02 EPS for the current fiscal year.
Hedge Funds Weigh In On Aura Biosciences
Several institutional investors and hedge funds have recently modified their holdings of AURA. New York State Common Retirement Fund lifted its stake in shares of Aura Biosciences by 134.3% during the first quarter. New York State Common Retirement Fund now owns 6,252 shares of the company's stock valued at $138,000 after buying an additional 3,584 shares during the period. Decheng Capital Management III Cayman LLC purchased a new position in shares of Aura Biosciences during the first quarter valued at approximately $4,620,000. Bank of New York Mellon Corp purchased a new position in shares of Aura Biosciences during the first quarter valued at approximately $319,000. BlackRock Inc. increased its position in Aura Biosciences by 15.2% during the first quarter. BlackRock Inc. now owns 275,027 shares of the company's stock worth $6,050,000 after purchasing an additional 36,244 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Aura Biosciences by 1.0% during the first quarter. Vanguard Group Inc. now owns 228,633 shares of the company's stock worth $5,030,000 after purchasing an additional 2,375 shares during the last quarter. Hedge funds and other institutional investors own 53.96% of the company's stock.Wall Street Analysts Forecast Growth
Separately, JMP Securities upped their price target on shares of Aura Biosciences from $26.00 to $30.00 and gave the company a "market outperform" rating in a report on Friday, November 11th.
About Aura Biosciences
(Get Rating)
Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
Featured Articles
- Get a free copy of the StockNews.com research report on Aura Biosciences (AURA)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.